These results suggest that SLURP1, LY6D, WFDC1, NOV, and GSTM3 are closely associated with the development of bladder cancer and have value as potential therapeutic targets, warranting further functional validation and clinical research. The gene discussed is GSTM3; the disease is urinary bladder cancer.